Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this multi-center Phase II trial is to examine the impact of
pemetrexed/carboplatin in the preoperative treatment of patients with select stage IB, II,and
III non-squamous NSCLC. Because patients with non-squamous type NSCLC have been shown to have
better survival rates than patients with squamous tumors when given pemetrexed with a
platinum agent, only patients with non-squamous NSCLC (adenocarcinoma, large cell, and
undifferentiated), not including squamous histology, will be allowed to participate in this
study. If this novel regimen proves to be safe and active in this setting, it will provide
rationale for further investigation in a larger, prospective, randomized trial.